8 withdrawn. 8 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Withdrawn 8 |
| Phase 3 | 3 | Withdrawn 3 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria Ritlecitinib - Chronic Spontaneous Urticaria, CSU | Phase 2 | Withdrawn | Ahuva D Cices | 2025-12-31 | 2025-12-09 | |
| A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria MTPS9579A, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Withdrawn | Genentech, Inc. | 2022-07-31 | 2022-11-18 | |
| Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema GNR-038, 50 МЕ/ kg, GNR-038, 100 МЕ/ kg, Berinert®, 20 МЕ/ kg - Hereditary Angioedema | Phase 2 / Phase 3 | Withdrawn | AO GENERIUM | 2021-12-01 | 2022-02-04 | |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria Tirabrutinib, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Withdrawn | Gilead Sciences | 2021-07-01 | 2021-07-28 | |
| Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema Ecallantide subcutaneous dosing - Hereditary Angioedema Types I and II | Phase 2 | Withdrawn | NYU Langone Health | 2013-08-01 | 2023-03-31 | |
| Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema ecallantide - Hereditary Angioedema (HAE) | Phase 2 / Phase 3 | Withdrawn | Shire | 2012-06-01 | 2021-05-18 | |
| Etanercept for the Treatment of Chronic Urticaria etanercept, placebo - Chronic Idiopathic Urticaria | Phase 2 / Phase 3 | Withdrawn | University of Utah | 2010-12-01 | 2015-06-02 | |
| A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease XOMA 052 - Muckle Wells Syndrome, Autoinflammatory | Phase 1 / Phase 2 | Withdrawn | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2010-08-27 | 2017-07-02 |
Chronic Urticaria (4) · Angioedemas, Hereditary (3) · Angioedema (1) · Behcet Syndrome (1) · Cryopyrin-Associated Periodic Syndromes (1) · Genetic Diseases, Inborn (1) · Hereditary Angioedema Types I and II (1) · Hypersensitivity (1) · Immune System Diseases (1)
Hypersensitivity, Immediate (8) · Skin Diseases (8) · Skin Diseases, Vascular (8) · Skin and Connective Tissue Diseases (8) · Hypersensitivity (7) · Immune System Diseases (7) · Chronic Disease (5) · Disease Attributes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Cardiovascular Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Vascular Diseases (4) · Genetic Diseases, Inborn (3)
Complement C1 Inhibitor Protein (1) · Etanercept (1) · PF-06651600 (1) · ecallantide (1) · gevokizumab (1) · tirabrutinib (1)
AO GENERIUM (1) · Ahuva D Cices (1) · Genentech, Inc. (1) · Gilead Sciences (1) · NYU Langone Health (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Shire (1) · University of Utah (1)
United States (4) · Russia (1)
Ahuva Cices, MD (1) · Christopher Hull, MD (1) · Mark A Davis-Lorton, MD (1) · Oksana A. Markova, MD (1)